PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer
The main purpose of this study is to validate the efficacy and safety of anti-PD-1 in combination with neoadjuvant chemotherapy in women with advanced ovarian cancer.
Ovarian Cancer|Neoadjuvant Chemotherapy|Anti-PD-1|Neoadjuvant Immunotherapy
DRUG: BGB-A317|DRUG: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
Progression-free survival(PFS), 12 months progression-free survival rate will be estimated, and 95% confidence intervals will be calculated., 12 months
R0 rate, R0 rate of IDS(interval debulking surgery) after neoadjuvant chemotherapy(after the completion of 3rd cycle), after interval debulking surgery for one week|CRR, CRR is defined as the percentage of the participants in the ITT population who have a Complete Response or Partial Response. The CRR will be assessed by a blind independent central reviewer per RECIST 1.1, 3 months|PRR, At interval cytoreduction pathologic complete remission rate will be measured using RECIST and immune-related response criteria., 3 months|OS, OS is defined as the time from the date of randomization until death., 5 years|AEs, Proportion of patients with grade 3 or more treatment-related adverse events(except hematologic toxicity) graded by CTCAE v5 in neoadjuvant chemotherapy, 3 months
The main purpose of this study is to validate the efficacy and safety of anti-PD-1 in combination with neoadjuvant chemotherapy in women with advanced ovarian cancer.